Braden Michael Leonard
CIK 1373603 · last filed 2026-10-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BBW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ZIONSVILLE, IN 46077
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OM | 10%+ Owner | 2,764,610 | $4.08 | $11.28M | $870.3K | 3 | 2026-10-05 |
| ACRS | 10%+ Owner | 13,950,000 | $3.79 | $52.87M | $4.23M | 8 | 2026-04-27 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | 10%+ Owner | 2,149,880 | $4.36 | $9.37M | $1.41M | 11 | 2025-12-05 |
| ASTC | 10%+ Owner | 0 | $5.01 | $0 | -$815.2K | 8 | 2025-10-07 |
| ANTX | 10%+ Owner | 3,017,432 | $3.63 | $10.95M | -$1.53M | 3 | 2025-06-16 |
| OKUR | 447,815 | $2.48 | $1.11M | $0 | 1 | 2024-10-09 | |
| OnKure Therapeutics, Inc. (RPHM) Delisted | 10%+ Owner | 447,817 | $18.20 | $8.15M | $1.73M | 5 | 2024-09-26 |
| Talis Biomedical Corp (TLIS) Delisted | 10%+ Owner | 217,951 | $2.84 | $619.0K | $56.1K | 1 | 2024-08-28 |
| Tectonic Therapeutic, Inc. (AVRO) Delisted | 10%+ Owner | 405,948 | $16.80 | $6.82M | $971.5K | 1 | 2024-05-15 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 499,444 | $14.59 | $7.29M | -$9.40M | 9 | 2023-01-05 |
| RVP | 10%+ Owner | 1,076,075 | $0.58 | $625.2K | -$2.08M | 7 | 2022-12-29 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 6,760,570 | $0.49 | $3.35M | $936.1K | 4 | 2022-12-21 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | 10%+ Owner | 6,590,000 | $1.10 | $7.25M | $4.50M | 2 | 2022-11-23 |
| Disc Medicine, Inc. (GMTX) Delisted | 10%+ Owner | 524,750 | $13.50 | $7.08M | $1.29M | 2 | 2022-10-27 |
| BBW | 1,423,043 | $23.78 | $33.84M | -$11.65M | 33 | 2017-10-02 | |
| ProPhase Labs, Inc. (PRPH) Delisted | 10%+ Owner | 62,732 | $0.11 | $6.9K | -$3.16M | 7 | 2017-10-02 |
Recent Filings · Page 5 of 12
111 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-05 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,250,000 | -$5.00M | EDGAR |
| 2023-01-04 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −1,250,000 | -$5.00M | EDGAR |
| 2022-12-30 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −20,000 | -$80.8K | EDGAR |
| 2022-12-29 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −20,000 | -$80.8K | EDGAR |
| 2022-12-29 | RVP | Sell (S) | −3,000,000 | -$4.80M | EDGAR |
| 2022-12-27 | Enliven Therapeutics, Inc. (IMRA) Delisted | Sell (S) | −50,000 | -$203.0K | EDGAR |
| 2022-12-21 | Metacrine, Inc. (MTCR) Delisted | Buy (P) | +271,605 | $107.6K | EDGAR |
| 2022-12-02 | ASTC | Buy (P) | +190,971 | $65.6K | EDGAR |
| 2022-11-30 | RVP | Sell (S) | −252,400 | -$505.5K | EDGAR |
| 2022-11-25 | ASTC | Buy (P) | +75,000 | $24.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.